Navigation Links
Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain

Nutra Pharma has completed submission of the final Nyloxin OTC and Nyloxin Rx packaging and labeling to the Food and Drug Administration (FDA). This registration is considered the final step required by the FDA to begin selling Nyloxin OTC and Nyloxin Rx in the United States for the treatment of chronic pain.

Plantation, FL (Vocus) December 7, 2009 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted the final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Nyloxin OTC, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, a prescription treatment for severe (Stage 3) chronic pain.

“Completing the FDA registration for Nyloxin OTC and Nyloxin Rx is an important and required step towards introducing our Nyloxin-branded pain relievers throughout domestic and international markets,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma. “With the FDA registration now completed, we plan to immediately move forward with our launch of Nyloxin Rx here in the United States, while we finalize our international drug registrations in Canada, Europe and South America for both our prescription and over-the-counter formulations,” he concluded.

The Company first introduced Nyloxin OTC in November as a treatment for moderate to severe (Stage 2) chronic pain. Nyloxin OTC is similar to the Company’s recently launched pain reliever, Cobroxin, and will be available internationally as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additionally, the Company introduced Nyloxin Rx in October as a prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one’s ability to fully function.

Both Nyloxin OTC and Nyloxin Rx are produced by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, and do not rely on the use of opioids or acetaminophen for their pain relieving action.

About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Completing the FDA registration for Nyloxin OTC and Nyloxin Rx should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

`# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Nutra Pharma Announces Upcoming Webinar to Discuss the Company's Over-the-Counter (OTC) and Prescription Treatments for Chronic Pain
2. Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks
3. Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution
4. Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever
5. Vivakor Presents at Nutraceutical Event
6. Reportlinker Adds US World Nutraceutical Ingredients Industry
7. RZN Nutraceuticals Receives United States Patent & Trademark Office Notice of Allowance for Proprietary HerbaZorb(TM) Absorption and Delivery System Technology Used in Popular Arthri-Zen Relief(R) and Migra-Zen Relief PLUS(R) Products
8. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
9. NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions
10. NutraCea Announces Additions to Management Team; Chief Operating Officer Extends Employment Contract
11. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
Post Your Comments:
Related Image:
Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: